Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare stocks to buy with highest upside potential. TD Cowen cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $80 on May 29, maintaining a Buy rating on the shares and stating that the firm updated its model to account for the latest Watchman update and related variables. TD Cowen moved to the bottom of the company’s organic sales growth guidance for both Q2 and the full year.
Boston Scientific Corporation also received a rating update from BofA in a separate development. BofA cut the price target on Boston Scientific Corporation to $68 from $105 on May 18, reaffirming a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies last week in Las Vegas, it updated several price targets for “the new reality of medtech valuations” in a year of few product cycles, inflation kicking up post-war, ACA, and utilization worries, and “data centers over healthcare”.
Boston Scientific Corporation manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
